, Tracking Stock Market Picks
Enter Symbol:
Rating: OMED

Oncomed Pharmaceuticals Inc. (NASDAQ: OMED) rated to Outperform by Leerink Swann

Monday,  Aug 12, 2013  9:25 AM ET by Dave Ficere

Leerink Swann
rated Oncomed Pharmaceuticals Inc. (NASDAQ: OMED) to Outperform.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy